Grothey A - Search Results

1

WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype.

Zimmer K, Puccini A, Xiu J, Baca Y, Spizzo G, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, Kocher F, Seeber A. Zimmer K, et al. Among authors: grothey a. Cancers (Basel). 2020 May 22;12(5):1319. doi: 10.3390/cancers12051319. Cancers (Basel). 2020. PMID: 32455893 Free PMC article.

2

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Grothey A, et al. J Clin Oncol. 2004 Apr 1;22(7):1209-14. doi: 10.1200/JCO.2004.11.037. J Clin Oncol. 2004. PMID: 15051767

3

A review of oxaliplatin and its clinical use in colorectal cancer.

Grothey A, Goldberg RM. Grothey A, et al. Expert Opin Pharmacother. 2004 Oct;5(10):2159-70. doi: 10.1517/14656566.5.10.2159. Expert Opin Pharmacother. 2004. PMID: 15461551 Review.

4

The continuum of care: a paradigm for the management of metastatic colorectal cancer.

Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. Goldberg RM, et al. Among authors: grothey a. Oncologist. 2007 Jan;12(1):38-50. doi: 10.1634/theoncologist.12-1-38. Oncologist. 2007. PMID: 17227899 Free article. Review.

5

Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.

Grothey A, Marshall JL. Grothey A, et al. Oncology (Williston Park). 2007 Apr;21(5):553-64, 566; discussion 566-8, 577-8. Oncology (Williston Park). 2007. PMID: 17536342 Free article.

6

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.

Lenz HJ, Chu E, Grothey A. Lenz HJ, et al. Among authors: grothey a. Clin Adv Hematol Oncol. 2008 Dec;6(12):1-13, 14-6. Clin Adv Hematol Oncol. 2008. PMID: 19378369

7

Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Heun JM, et al. Among authors: grothey a. Oncologist. 2011;16(6):859-67. doi: 10.1634/theoncologist.2011-0064. Epub 2011 May 31. Oncologist. 2011. PMID: 21632455 Free PMC article. Clinical Trial.

8

KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.

Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ; NCI GI Steering Committee Colon Cancer Task Force. Blanke CD, et al. Among authors: grothey a. Oncologist. 2011;16(8):1061-8. doi: 10.1634/theoncologist.2011-0011. Epub 2011 Jul 7. Oncologist. 2011. PMID: 21737577 Free PMC article.

9

Explaining the unexplainable: EGFR antibodies in colorectal cancer.

Grothey A, Lenz HJ. Grothey A, et al. J Clin Oncol. 2012 May 20;30(15):1735-7. doi: 10.1200/JCO.2011.40.4194. Epub 2012 Apr 2. J Clin Oncol. 2012. PMID: 22473160 No abstract available.

10

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Alberts SR, et al. Among authors: grothey a. JAMA. 2012 Apr 4;307(13):1383-93. doi: 10.1001/jama.2012.385. JAMA. 2012. PMID: 22474202 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

378 results

Search Page